The government has placed orders for 1 crore (10 million) additional doses of Covishield from Serum Institute of India and 45 lakh (4.5 million) more doses of Covaxin from Bharat Biotech, officials of the two vaccine makers said on Tuesday.
India's COVID-19 vaccination drive was launched by Prime Minister Narendra Modi on January 16.
Serum Institute has received another order from the government for 10 million doses of Covishield, a company official said in response to a query.
The government had earlier placed a purchase order with Serum Institute of India (SII) for 1.1 crore doses of AstraZeneca-Oxford COVID-19 vaccine, Covishield.
When asked, a Bharat Biotech spokesperson said, "The company has received a letter of comfort from the Government of India to supply another 4.5 million (or 45 lakh) doses''.
The spokesperson also added that Bharat Biotech will also be exporting its COVID-19 vaccine, Covaxin, to Brazil and the United Arab Emirates.
The company is also likely to export the vaccine to the Philippines and other South Asian countries, the spokesperson said.
The government had earlier placed an order for 55 lakh doses of Covaxin from Bharat Biotech.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)